AUNA

AI Memo

Auna

As of 2026-10-01/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-01 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

October 22 Investor Day • 2026-10-22

Base target: $5 / p=45% prob

Biggest risk

Revenue growth has not yet translated into comparable profit growth: second-quarter adjusted EBITDA fell 9% FX-neutral, with Mexico mix and talent costs, Colombia margins and Peru billing penalties weighing on results [#SEC-6K-2026-08-18]. Persistent pressure would weaken the recovery thesis.

Invalidation

Break below $4 or thesis failure.

What would change my mind?

Higher patient volumes, improved collections and disciplined investment could turn Auna's revenue growth into EBITDA growth and reduce leverage. The company reported second-quarter operating cash flow up 45% year over year and leverage of 3.6x [#SEC-6K-2026-08-18].

Research note

Recommendation

—

Confidence

medium

As of

2026-10-01

Base target

p=45%

Bull target

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Second-half margin recovery against reduced EBITDA expectations
Auna Lima Sur capacity opening
Higher patient volumes, improved collections and disciplined investment could turn Auna's revenue growth into EBITDA growth and reduce leverage.

BearKey bullets

Foreign-exchange movements and Colombia payer conditions complicate reported results and cash conversion [#SEC-6K-2026-08-18].
Leverage remained 3.6x at June 30, above Auna's medium-term target of less than 3.0x [#SEC-6K-2026-08-18].
Peru billing-reconciliation penalties and higher pharmacy and personnel costs may persist longer than management expects [#SEC-6K-2026-08-18].

WatchKey bullets

October 22 Investor Day

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $5 (p=45%)

Target spread vs base: +23% / -28%

Scenario probabilities

Bull Target: $7 (p=30%)Base Target: $5 (p=45%)Bear Target: $4 (p=25%)

Commentary

Monitoring view, not a confirmed earnings rerating. The first close after the August 18 release was nearly unchanged at $5.43 versus $5.42, despite a wide intraday range; the September 30 packet anchor was $4.98. [Historical prices](https://stockanalysis.com/stocks/auna/history/) The company release supports the operating figures, but reliable post-print consensus-surprise and analyst-revision evidence is limited. Zeroes in optional sentiment metrics denote unavailable data, not measured neutral readings.

As of 2026-10-01 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Second-half margin recovery against reduced EBITDA expectations
Auna Lima Sur capacity opening

Scenarios

Bull Target (Scenario probability)

$7 / p=30% prob

Base Target (Scenario probability)

$5 / p=45% prob

Bear Target (Scenario probability)

$4 / p=25% prob

Analysis 2026-10-01 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-22
October 22 Investor Day
Auna has scheduled its first Investor Day to discuss strategy and financial priorities across Mexico, Peru and Colombia [#IR-2026-09-16]. Specific, measurable margin and deleveraging milestones would improve visibility; the event itself does not establish that they will be achieved. [Company announcement](https://aunainvestors.com/Spanish/actualidad/prensa/detalle-de-noticias/2026/Auna-to-Host-2026-Investor-Day-on-October-22-2026/default.aspx)
Prob 95.00% • Move 5.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Second-half margin recovery against reduced EBITDA expectations
2026-12-31
Second-quarter revenue rose 9% FX-neutral, but adjusted EBITDA fell 9%. Auna maintained approximately 12% full-year FX-neutral revenue growth guidance while expecting adjusted EBITDA growth toward the low end of its 10%–14% range, excluding specified Peru billing penalties [#SEC-6K-2026-08-18] [#EARNINGS-TRANSCRIPT-2026Q2]. Subsequent results must show that Mexico service mix, Colombia contract pricing and Peru billing costs permit margin recovery. [SEC-filed earnings release](https://www.sec.gov/Archives/edgar/data/1799207/000095010326012579/dp251949_ex9901.htm)
Prob 50% • Move 14% • Priced-in 40%
Auna Lima Sur capacity opening
2028-03-31
Auna said it had begun mobilization for an asset-light Lima clinical facility with an operating room, chemotherapy bays and 30 inpatient beds, targeting operation between late 2027 and early 2028 [#SEC-6K-2026-08-18]. Timing, utilization and returns remain unproven. [SEC-filed earnings release](https://www.sec.gov/Archives/edgar/data/1799207/000095010326012579/dp251949_ex9901.htm)
Prob 60% • Move 7% • Priced-in 25%

Risks

Foreign-exchange movements and Colombia payer conditions complicate reported results and cash conversion [#SEC-6K-2026-08-18].
Leverage remained 3.6x at June 30, above Auna's medium-term target of less than 3.0x [#SEC-6K-2026-08-18].
Peru billing-reconciliation penalties and higher pharmacy and personnel costs may persist longer than management expects [#SEC-6K-2026-08-18].
Second-quarter adjusted EBITDA declined despite revenue growth; full-year EBITDA growth is now expected toward the low end of guidance [#SEC-6K-2026-08-18].

Peers

Symbol	Summary
CTEV	Similar market capitalization in the packet, but a healthcare-cost-management business rather than a direct hospital-and-health-plan operating peer; unsuitable for a clean valuation multiple.
CLPT	Similar market capitalization in the packet, but its medical-device model differs materially from Auna's integrated care delivery and payer exposure. Peer comparisons have low weight.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-01

Loading AI feed…

Symbol

Summary

CTEV

Similar market capitalization in the packet, but a healthcare-cost-management business rather than a direct hospital-and-health-plan operating peer; unsuitable for a clean valuation multiple.

CLPT

Similar market capitalization in the packet, but its medical-device model differs materially from Auna's integrated care delivery and payer exposure. Peer comparisons have low weight.